StreetInsider.com News Articles

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

“Daiichi Sankyo delivered strong revenue growth in the first quarter of fiscal year 2026 as we began execution of our new Five-Year Business Plan,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “Three new U.S. approvals for Enhertu and

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fri, 31 Jul 2026 04:30:00 -0400

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Fri, 31 Jul 2026 02:30:00 -0400

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
Datroway now approved for two breast cancer indications in the EU

TOKYO--(BUSINESS WIRE)-- Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Fri, 31 Jul 2026 02:30:00 -0400

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
Datroway now approved for two breast cancer indications in the EU

Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Fri, 31 Jul 2026 02:30:00 -0400

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
Datroway now approved for two breast cancer indications in the EU

Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo